Sorry, you need to enable JavaScript to visit this website.

All materials and content available on the website are of strictly non-promotional nature and only intended for healthcare professionals (HCPs) practicing in Europe. Kindly note that materials and content are not intended for any specific country and approval conditions for products may vary from country to country. Before prescribing any product, always refer to the approved label in the relevant country and/or the Summary of Product Characteristics.

  • Testosterone deficiency

Robust evidence on prostate safety of testosterone replacement therapy

Explore the science
  • Testosterone deficiency

Robust evidence on testosterone replacement therapy for the prevention and correction of anaemia in men with hypogonadism

Explore the science
  • Testosterone deficiency

Robust evidence on the safety of testosterone replacement therapy in pre-diabetic and diabetic patients

Explore the science
  • Testosterone deficiency

The TRAVERSE study: redefining what we knew about the safety profile of testosterone replacement therapy

Explore the science
  • Testosterone deficiency

Depressive syndromes in men with hypogonadism, the impact of testosterone replacement therapy

Explore the science
  • Testosterone deficiency

Robust evidence on cardiovascular safety of testosterone replacement therapy

Explore the science
  • Testosterone deficiency

Infographic of testosterone deficiency: its symptoms, diagnosis and treatment

Explore the science
  • Glomerular Disease

New treatment options for IgAN, along with real-world data for sparsentan: Comprehensive review by Prof. Jörg Latus

Explore the science
  • IgA Nephropathy

Innovative approaches to IgAN therapy: Summary presentation from Prof. Huynh Do

Explore the science